N-乙基金刚烷-1-胺盐酸盐

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N-乙基金刚烷-1-胺盐酸盐
• 英文名称: N-(adamantyl-1)-N-ethylamine hydrochloride
• 英文别名: 1-Ethylamino-adamantan-hydrochlorid；N-ethyladamantan-1-amine;hydron;chloride
• 化学式: C₁₂H₂₁N*ClH
• mdl: MFCD01674015
• 分子量: 215.766
• InChiKey: QBPTZTSMOGAMPF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.26
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-溴丙炔 、 N-乙基金刚烷-1-胺盐酸盐 在 碳酸氢钠 作用下， 以 乙醇 为溶剂， 生成 1-(N-Ethyl-N-propargyl)-adamantan
  参考文献：
  名称：

  Arya,V.P. et al., Indian Journal of Chemistry, 1972, vol. 10, p. 686 - 690

  摘要：

  DOI：

文献信息

• Methods for preparing antiviral calanolide compounds
  申请人：Sarawak Medichem Pharmaceuticals, Inc.

  公开号：US20020013480A1

  公开（公告）日：2002-01-31

  The present invention relates to methods for preparing 2,2-dimethyl-5-acyloxy-10-propyl-2H,8H-benzo[ 1,2-b:3,4-b ′]dipyran-8-one (5) and 2,2-dimethyl-5-hydroxy- 10-propyl-2H,8H-benzo[1,2-b:3,4-b ′]dipyran-8-one (6) and their use as intermediates for the synthesis of antiviral calanolide compounds. For example, Fries rearrangement on compound 5 or Friedel-Crafts reaction on 6, yields intermediate 2,2-dimethyl-5-hydroxy-6-propionyl-10-propyl-2H,8H-benzo[1,2-b:3,4-b′]dipyran-8-one (4), which, in turn, can be converted to (+)-calanolide A and (−)-calanolide B. The coupling of compound 6 with the appropriate chiral molecule under Mitsunobu or nucleophilic displacement leads to the asymmetric synthesis of antiviral calanolide compounds.

  本发明涉及制备2,2-二甲基-5-酰氧基-10-丙基-2H,8H-苯并[1,2-b:3,4-b′]二吡喃-8-酮（5）和2,2-二甲基-5-羟基-10-丙基-2H,8H-苯并[1,2-b:3,4-b′]二吡喃-8-酮（6）的方法，以及它们作为抗病毒卡纳洛利德化合物合成的中间体的用途。例如，对化合物5进行Fries重排或对6进行Friedel-Crafts反应，得到中间体2,2-二甲基-5-羟基-6-丙酰基-10-丙基-2H,8H-苯并[1,2-b:3,4-b′]二吡喃-8-酮（4），进而可以转化为（+）-卡纳洛利德A和（-）-卡纳洛利德B。将化合物6与适当的手性分子在Mitsunobu或亲核取代下偶联，可实现抗病毒卡纳洛利德化合物的不对称合成。
• Novel coumarin and chromene compounds and methods of preparation and use thereof for treating or preventing viral infections
  申请人：——

  公开号：US20030176494A1

  公开（公告）日：2003-09-18

  The present invention relates to methods of preparation and use of coumarin and chromene compounds for treating or preventing viral infections.

  本发明涉及制备和使用香豆素和咖啡因类化合物用于治疗或预防病毒感染的方法。
• Calanolide analogues and methods of their use
  申请人：Sarawak Medichem Pharmaceuticals,Inc.

  公开号：US20020013478A1

  公开（公告）日：2002-01-31

  Calanolide analogues that demonstrate potent antiviral activity against many viruses are provided. Also provided is a method of using calanolide analogues for treating or preventing viral infections. The calanolide analogues provided are obtained via syntheses employing chromene 4 and chromanone 7 as key intermediates.

  本文提供了表现出对许多病毒具有强效抗病毒活性的Calanolide类似物。还提供了使用Calanolide类似物治疗或预防病毒感染的方法。所提供的Calanolide类似物是通过使用柿蒂素4和柿酮7作为关键中间体进行合成获得的。
• Amentoflavone as an antiviral agent
  申请人：Advanced Life Sciences Inc.

  公开号：EP1245230A2

  公开（公告）日：2002-10-02

  Substantially purified antiviral biflavanoids robustaflavone, hinokiflavone, amentoflavone, agathisflavone, volkensiflavone, morelloflavone, rhusflavanone, succedaneaflavanone, GB-1a and GB-2a are provided. Antiviral fiflavanoid derivatives and salt forms thereof, e.g. robustaflavone tetrasulfate potassium salt, and methods for preparing the same are also disclosed. Pharmaceutical compositions which include the antiviral biflavanoids, derivatives or salts thereof are also provided. Also disclosed is an improved method for obtaining substantially pure robustaflavone from plant material. The biflavanoid compounds, derivatives or salts thereof of the invention may be used in a method for treating and/or preventing viral infections caused by viral agents such as influenza, e.g. influenza A and B; hepatitis, e.g. hepatitis B; human immunodeficiency virus, e.g. HIV-1; Herpes viruses (HSV-1 and HSV-2); Varicella Zoster virus (VZV); and measles.

  本研究提供了实质上纯化的抗病毒双黄酮类化合物--强力黄酮、桧黄酮、芒果黄酮、芒果黄酮、伏肯黄酮、麦卢黄酮、胡黄酮、琥珀黄酮、GB-1a 和 GB-2a。此外，还公开了抗病毒的五黄烷衍生物及其盐形式，例如强力黄酮四硫酸钾盐，以及制备方法。还提供了包括抗病毒双黄烷、衍生物或其盐的药物组合物。此外，还公开了一种从植物材料中获得高纯度强力黄酮的改进方法。本发明的双黄烷化合物、衍生物或其盐类可用于治疗和/或预防由病毒病原体引起的病毒感染，如流感，如甲型和乙型流感；肝炎，如乙型肝炎；人类免疫缺陷病毒，如 HIV-1；疱疹病毒（HSV-1 和 HSV-2）；水痘带状疱疹病毒（VZV）；以及麻疹。
• Biflavanoids and derivatives thereof as antiviral agents
  申请人：Advanced Life Sciences, Inc.

  公开号：US20020068757A1

  公开（公告）日：2002-06-06

  Substantially purified antiviral biflavanoids robustaflavone, hinokiflavone, amentoflavone, agathisflavone, volkensiflavone, morelloflavone, rhusflavanone, succedaneaflavanone, GB-1a, and GB-2a are provided. Antiviral biflavanoid derivatives and salt forms thereof, e.g., robustaflavone tetrasulfate potassium salt, and methods for preparing the same are also disclosed. Pharmaceutical compositions which include the antiviral biflavanoids, derivatives or salts thereof are also provided alone or in combination with at least one antiviral agent such as 3TC. Also disclosed is an improved method for obtaining substantially pure robustaflavone from plant material. The biflavanoid compounds, derivatives or salts thereof of the invention may be used in a method for treating and/or preventing viral infections caused by viral agents such as influenza, e.g., influenza A and B; hepatitis, e.g., hepatitis B; human immunodeficiency virus, e.g., HIV-1; Herpes viruses (HSV-1 and HSV-2); Varicella Zoster virus (VZV); and measles. For instance, semi-synthetic hexa-O-acetate and hexa-O-methyl ether derivatives of robustaflavone have been found to be effective in a method for treating or preventing hepatitis B viral infections. Compositions which include these robustaflavone derivatives along with methods for preparing and using the same are also provided. These compositions may be used alone or in combination with at least one antiviral agent such as 3TC.

  本研究提供了实质上纯化的抗病毒双黄酮类物质--强力黄酮、桧黄酮、芒果黄酮、茄黄酮、伏肯黄酮、更萝黄酮、胡黄酮、琥珀黄酮、GB-1a 和 GB-2a。此外，还公开了抗病毒双黄烷衍生物及其盐形式，例如强力黄酮四硫酸钾盐，以及制备方法。还提供了包括抗病毒双黄酮类化合物、衍生物或其盐类的药物组合物，这些药物组合物可单独使用，也可与至少一种抗病毒药物如 3TC 结合使用。此外，还公开了一种从植物材料中获得高纯度强力黄酮的改进方法。本发明的双黄烷化合物、衍生物或其盐类可用于治疗和/或预防由病毒病原体引起的病毒感染，如流感，如甲型和乙型流感；肝炎，如乙型肝炎；人类免疫缺陷病毒，如HIV-1；疱疹病毒（HSV-1和HSV-2）；水痘带状疱疹病毒（VZV）；以及麻疹。例如，在治疗或预防乙型肝炎病毒感染的方法中，发现了半合成的六-O-乙酸酯和六-O-甲醚衍生物强力黄酮。此外，还提供了包括这些强力黄酮衍生物的组合物以及制备和使用这些组合物的方法。这些组合物可单独使用，也可与至少一种抗病毒药物如 3TC 结合使用。